BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of ovarian research Jg. 16; H. 1; S. 231 - 16
Hauptverfasser:	Farokhi Boroujeni, Salar, Rodriguez, Galaxia, Galpin, Kristianne, Yakubovich, Edward, Murshed, Humaira, Ibrahim, Dalia, Asif, Sara, Vanderhyden, Barbara C.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 28.11.2023 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Analysis Angiogenesis Animals B7-H1 Antigen - genetics BRCA mutations BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Cancer Cancer therapies Care and treatment Cell death Clinical trials DNA damage DNA repair Female Genes, BRCA2 Genomes Gynecology Humans Immune checkpoint inhibitors Immunomodulation Immunotherapy Inflammation Medical prognosis Medicine Medicine & Public Health Mice Monoclonal antibodies Mutation Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism PARP inhibitors PD-L1 protein Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Reproductive Medicine RNA Survival Tumor microenvironment Tumor Microenvironment - genetics Tumors Immune checkpoint inhibitors mutations PARP inhibitors Ovarian cancer BRCA mutations
ISSN:	1757-2215, 1757-2215
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!